Clinical utility of 1:16 serum dilution as a predictor of response to therapeutic plasma exchange for HLA antibody-mediated rejection treatment and overall survival in lung transplant recipients: A two center study
The MFI of 1:16 serum dilution before 1st TPE may be utilized as a surrogate to predict response to TPE for AMR treatment and overall survival in LTR.
Authors
- Gerard J. Criner (ORCID: https://orcid.org/0000-0003-1267-3483)
- Tathagat Narula (ORCID: https://orcid.org/0000-0003-4631-9888)
- Norihisa Shigemura (ORCID: https://orcid.org/0000-0003-0438-1632)
- Olga Timofeeva (ORCID: https://orcid.org/0000-0002-9886-6683)
- Francisco Alvarez (ORCID: https://orcid.org/0000-0002-3692-9757)
- Elizabeth A. Godbey (ORCID: https://orcid.org/0000-0002-1042-1429)
- Francis Cordova (ORCID: https://orcid.org/0009-0004-7468-7121)
- Yoshiya Toyoda (ORCID: https://orcid.org/0000-0002-3990-5320)
- Mohamed Elrefaei (ORCID: https://orcid.org/0000-0002-2030-4779)
- Jasmine Kendrick
Institutions
- University of California, Los Angeles (US)
- Jacksonville College (US)
- Mayo Clinic in Florida (US)
- Temple University (US)
Publication Details
- Journal
- JHLT Open
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1016/j.jhlto.2025.100302
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00